

Review Form 1.7

Journal Name:	Asian Oncology Research Journal
Manuscript Number:	Ms_AORJ_107742
Title of the Manuscript:	Outcome of Organ Sparing Trimodality Treatment of Muscle Invasive Bladder Cancer
Type of the Article	

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</p> <p>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</p>	<p>1- article is interesting for the scientific community since it provides encouraging results from trimodal treatment. The overall survival rate at 59 vs (36 to 74% in the literature), The recurrence-free survival rate at 50%, Complete response rate at 66%, Salvage cystectomy 18% vs (14 to 20% in the literature)</p> <p>2- the title of the article is suitable</p> <p>3- yes</p> <p>4- yes</p> <p>5- yes</p> <p>6- interesting bibliography to propose: recommendations of the French association of urology 2022 and EAU 2023</p>	
<p>Minor REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p>	<p>1- Yes</p>	
<p>Optional/General comments</p>	<p>Interesting article, well written, however I have a few comments and questions:</p> <ul style="list-style-type: none"> - The patients received the same chemotherapy protocol?? (gemcitabine and cisplatin)? If not, please specify the percentage of each category? - Have you tried neoadjuvant chemotherapy in some of your patients? - Patient selection criteria: have you offered trimodal treatment only to patients not eligible for surgery? or offered to selected patients namely (complete resection, stage T2-T3 N0 M0, absence of diffuse CIS, absence of hydronephrosis, absence of major functional alteration of the bladder, in a patient informed and compliant with the planned rigorous follow-up) knowing well that the oncological results are not the same in the two categories? If so, did you have any differences in results between the two groups? - The percentage of complete TURBT before radio-chemotherapy? correlation with complete response rate? and overall survival rate. - The recidivism rate? in what mode? infiltrating or not?? treatment proposed for recurrence (resection or cystectomy) 	

[Review Form 1.7](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Kadouri Youssef
Department, University & Country	Regional Hospital Center of Guelmim, Mohammed V University, Morocco